Drug Price Trends for NDC 27808-0296

Average Pharmacy Cost for 27808-0296

Drug Name	NDC	Price/Unit ($)	Unit	Date
CELECOXIB 100 MG CAPSULE	27808-0296-01	0.07113	EACH	2026-03-18
CELECOXIB 100 MG CAPSULE	27808-0296-02	0.07113	EACH	2026-03-18
CELECOXIB 100 MG CAPSULE	27808-0296-02	0.07148	EACH	2026-02-18
CELECOXIB 100 MG CAPSULE	27808-0296-01	0.07148	EACH	2026-02-18

Best Wholesale Price for NDC 27808-0296

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 27808-0296

Last updated: February 25, 2026

What is NDC 27808-0296?

NDC 27808-0296 corresponds to Samidorphan/Olanzapine (OLZ/SAM), a combination drug approved by the FDA in 2021 for the treatment of schizophrenia and bipolar I disorder. It offers a novel mechanism targeting both positive symptoms and rapid weight gain associated with olanzapine monotherapy.

Current Market Landscape

Market Size and Growth

• The global psychiatric drugs market was valued at approximately $18.8 billion in 2022.
• The antipsychotics segment accounts for roughly $10 billion.
• Expected compound annual growth rate (CAGR): 4% from 2022 to 2027.

Competition

Compound	Market Approx. Size	Years on Market	Approval Year
Olanzapine (Zyprexa)	$4.5 billion	1996	1996
Risperidone (Risperdal)	$2.5 billion	1993	1993
Aripiprazole (Abilify)	$2.8 billion	2002	2002
Brexpiprazole (Rexulti)	$400 million	2015	2015
Cariprazine (Vraylar)	$300 million	2015	2015

Olanzapine-related patents and exclusivities have largely expired or are nearing expiration, opening space for generic competition. The introduction of OLZ/SAM aims to address weight gain side effects and improve compliance.

Prescriber Adoption

• The drug is positioned for patients requiring olanzapine therapy at high risk for weight gain.
• Initial prescriber uptake is cautious, constrained by its recent approval and existing lifelong treatments.

Insurance and Reimbursement

• Coverage foreseen through Medicare and private payers.
• Early reimbursement challenges seen with groundbreaking drugs, but expected to resolve as clinical benefits are confirmed.

Price Projections

Launch Price

• Initial list price estimated at around $500 per month, based on comparable drugs.
• Adjusted for combination therapy premiums, expected to be between $450 and $550 monthly.

Market Penetration and Growth

• Year 1: 10% of olanzapine-treated patient base (~1 million patients), approximately 100,000 patients.
• Year 3: 25% market share, around 250,000 patients.
• Year 5: Market share potentially reaching 40%, approximately 400,000 patients.

Revenue Projections (USD)

Year	Estimated Patients	Price per Patient	Total Revenue
2023	100,000	$500/month	$600 million
2024	200,000	$500/month	$1.2 billion
2025	300,000	$500/month	$1.8 billion
2026	400,000	$500/month	$2.4 billion

Key Factors Influencing Price and Market Adoption

• Competitive landscape with generics: pricing pressures expected.
• Clinical advantages: potential to command premium if weight loss benefits are confirmed.
• Payer acceptance: discounts or rebates may be introduced to favor reimbursement.
• Geographic expansion: U.S. market will dominate initially, with Europe and Asia following.

Risks and Challenges

• Accelerated generic entry could reduce prices.
• Patient and prescriber acceptance rates depend on perceived efficacy and safety.
• Long-term safety profile and post-market data may influence reimbursement and formulary inclusion.
• Prices may decline by 10-15% annually after peak adoption due to market competition.

Final Assessment

• The drug is positioned as a differentiated product targeting a significant unmet need.
• Revenue estimates suggest potential peak annual sales of approximately $2.4 billion by 2026.
• Price optimization strategies will be critical in balancing market penetration with profitability.

Key Takeaways

• The market for OLZ/SAM is competitive but underserved in weight management within antipsychotics.
• Initial list prices will be around $500/month, with revenues scaling as market share grows.
• Price pressures from generics and payer negotiations could impact margins.
• Pending clinical and real-world data will influence long-term market adoption.

FAQs

1. What differentiates OLZ/SAM from other antipsychotics?
   It offers a novel mechanism that mitigates weight gain, a common side effect of olanzapine.

2. What is the expected market share for OLZ/SAM in its first five years?
   Estimated from 10% initially to roughly 40%, depending on prescriber and patient acceptance.

3. How might generic entry affect the drug’s price?
   Generic competition could lower price points by 20-30% within three years post-launch.

4. Are there ongoing clinical trials that could influence market outlook?
   Yes, additional studies on long-term safety, efficacy, and weight management are underway.

5. What regions will generate the highest revenue?
   The U.S. will dominate early, with Europe, Japan, and expanding Asian markets contributing later.

---

References

[1] MarketWatch. (2023). Psychiatric drugs market size and forecasts.
[2] IQVIA. (2022). Global pharmaceutical market analysis.
[3] FDA. (2021). Olanzapine/Olanzapine + Samidorphan marketing approval documents.